source
- Novo Nordisk acquires three early-stage obesity programs from KallyopeNovo Nordisk announced the purchase of three early-stage obesity drug programs from New York‑based biotech Kallyope, expanding its metabolic pipeline. The acquired assets are not GLP‑1 incretins.…
- Electra Therapeutics raises $350 million in Nasdaq IPO to fund commercial expansionElectra Therapeutics announced that it priced its initial public offering on the Nasdaq at $350 million, becoming the 21st biotech to go public in 2026. The Bay Area‑based company said the capital…